Specific interleukin-1 gene polymorphisms in Turkish patients with Behçet's disease

Experimental Dermatology

Volumn 14, Issue 2, 2005, Pages 124-129

  Coskun, Mesut ^a   Bacanli, Ali ^a   Sallakci, Nilgun ^a   Alpsoy, Erkan ^a   Yavuzer, Ugur ^a   Yegin, Olcay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; Gene polymorphisms; Interleukin 1 receptor antagonist genes; Interleukin 1 ; Interleukin 1

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ALLELE; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TANDEM REPEAT; TURKEY (REPUBLIC);

ADULT; ALLELES; BEHCET SYNDROME; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-1; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TURKEY;

EID: 14044250221     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2005.00253.x     Document Type: Article

References (45)

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999: 341: 1284-1291.
2. Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behçet disease: immunological aspects. Yonsei Med J 1997: 38: 350-358.
3. Alpsoy E, Yilmaz E, Coskun M, Savas A, Yegin O. HLA antigens and linkage disequilibrium patterns in Turkish Behçet's patients. J Dermatol 1998: 25: 158-162.
4. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001: 19 (5 Suppl. 24): S6-S12.
5. Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997: 38: 444-454.
6. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 1997: 14: 21-32.
7. Alpsoy E, Cayirli C Er H, Yilmaz E. The levels of plasma interleukin-2 and soluble interleukin-2r in Behçet's disease; A marker of disease activity. J Dermatol 1998: 25: 513-516.
8. Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patient's with Behçet's disease. Clin Exp Immunol 1990: 79: 28-34.
9. Lew W, Lee S H, Bang D, Lee S, Kim J C, Chung T H. Serum tumor necrosis factor, interleukin-1-beta and interleukin-6 levels in Behçet's disease. Ann Dermatol 1993: 5: 69-73.
10. Mege J L, Dilsen N, Sanguedolce V et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6; IL-8 and increased neutrophil superoxide generation in Behçet's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993: 20: 1544-1549.
11. Itoh R, Takenaka T, Okitsu-Negishi S, Matsushima K, Mizogouchi M. Interleukin-8 in Behçet's disease. J Dermatol 1994: 21: 397-404.
12. Sayinalp N, Özcebe O I, Özdemir O, Haznedaroglu I C, Dündar S, Kirazli S. Cytokines in Behçet's disease. J Rheumatol 1996: 23: 321-322.
13. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002: 31 (4): 205-210.
14. Alpsoy E, Kodelja V, Goerdt S, Orfanos C E, Zouboulis C C. Serum of patients with Behçet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003: 206 (3): 225-232.
15. Durum S K, Schmidt J A, Oppenheim J J. Interleukin 1: an immunological perspective. Annu Rev Immunol 1985: 3: 263-287.
16. Katsantonis J, Adler Y, Orfanos C E, Zoubulis C H C. Adamantiades-Behçet's disease: Serum IL-8 is a more reliable marker for disease activity than c-reactive protein and erythrocyte sedimentation rate. Dermatology 2000: 201: 37-39.
17. Ahmad T, Wallace G R, James T et al. Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms?. Arthritis Rheum 2003: 48: 807-813.
18. Kim E H, Mok J W, Bang D S, Lee E S, Lee S N, Park K S. Intercellular adhesion molecule-1 polymorphisms in Korean patients with Behçet's disease. J Korean Med Sci 2003: 18: 415-418.
19. Karasneh J, Hajeer A H, Barrett J, Ollier W E, Thornhill M, Gul A. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behçet's disease. Rheumatology (Oxford) 2003: 42: 860-864.
20. Nothwang H G, Strahm B, Denich D et al. Molecular cloning of the interleukin-1 gene cluster: construction of an integrated YAC/PAC contig and a partial transcriptional map in the region of chromosome 2q13. Genomics 1997: 41: 370-378.
21. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990: 335: 1078-1080.
22. McDowell T L, Symons J A, Ploski R, Forre O, Duff G W. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995: 38: 221-228.
23. di Giovine F S, Takhsh E, Blakemore A I, Duff G W. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992: 1: 450.
24. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992: 22: 396-402.
25. Tarlow J K, Blakemore A I, Lennard A et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993: 91: 403-404.
26. Vohnout B, Di Castelnuovo A, Trotta R et al. Interleukin-1 gene cluster polymorphisms and risk of coronary artery disease. Haematologica 2003: 88 (1): 54-60.
27. Loughrey B V, Maxwell A P, Fogarty D G et al. An interleukin 1B allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy. Cytokines 1998: 10: 984-988.
28. Stokkers P C, van Aken B E, Basioski N, Reitsma P H, Tytgat G N, van Deventer S J. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 1998: 43: 33-39.
29. Gore E A, Sanders J J, Pandey J P, Palesch Y, Galbraith G M. Interleukin-1beta+3953 allele 2: association with disease status in adult periodontitis. J Clin Periodontol 1998: 25: 781-785.
30. Buchs N, di Giovine F S, Silvestri T, Vannier E, Duff G W, Miossec P. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun 2001: 2 (4): 222-228.
31. Nemetz A, Nosti-Escanilla M P, Molnar T et al. IL-1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999: 49: 527-531.
32. Reich K, Mossner R , Konig I R, Westphal G, Ziegler A, Neumann C. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1 beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002: 118 (1): 155-163.
33. Shirodaria S, Smith J, McKay I J, Kennett C N, Hughes F J. Polymorphisms in the IL-1A gene are correlated with levels of interleukin-1 alpha protein in gingival crevicular fluid of teeth with severe periodontal disease. J Dent Res 2000: 79 (11): 1864-1869.
34. Hulkkonen J, Laippala P, Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw 2000: 11 (2): 251-255.
35. Hutyrova B, Lukac J, Bosak V, Buc M, du Bois R, Petrek M. Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis. J Rheumatol 2004: 31 (1): 81-84.
36. Ravindran J S, Owen P, Lagan A et al. Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. Rheumatology (Oxford) 2004: 43 (1): 22-26.
37. Parks C G, Cooper G S, Dooley M A et al. Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States. Ann Rheum Dis 2004: 63 (1): 91-94.
38. Danis V A, Millington M, Hyland V J, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995: 99 (2): 303-310.
39. Mansfield J C, Holden H, Tarlow J K et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994: 106 (3): 637-642.
40. Blakemore A I, Tarlow J K, Cork M J, Gordon C, Emery P, Duff G W. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994: 37 (9): 1380-1385.
41. Tarlow J K, Clay F E, Cork M J et al. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dermatol 1994: 103 (3): 387-390.
42. Clay F E, Cork M J, Tarlow J K et al. Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus. Hum Genet 1994: 94 (4): 407-410.
43. Wilkinson R J, Patel P, Llewelyn M et al. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med 1999: 21: 189 (12): 1863-1874.
44. Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B. Review of the clinical manifestations' chronology in 60 patients with Behçet's disease. Dermatology 2003: 117: 354-356.
45. Celenligil-Nazliel H, Kansu E, Ebersole J L. Periodontal findings and systemic antibody responses to oral microorganisms in Behçet's disease. J Periodontol 1999: 70 (12): 1449-1456.